Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AV
Avalyn Pharma Inc. Common Stock
AVLN
Mkt Cap
$1.05B
Volume
174.88K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AV
AVLN
AV
Avalyn Pharma Inc. Common Stock
AVLN
News
·
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Mkt Cap
$1.09B
Volume
174.88K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Avalyn Pharma announced two poster presentations at the European Respiratory Society International Congress 2026 in Barcelona. The presentations will cover patient perspectives on IPF clinical trial participation and in silico modeling of AP01, the company's nebulized pirfenidone formulation. Avalyn has completed enrollment of its Phase 2b MIST trial with 398 patients, with topline data expected in the second half of 2027.
GlobeNewswire Inc. · Aug 24, 2026
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma announced completion of target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis. The global, randomized, double-blinded, placebo-controlled trial is evaluating two doses of AP01 against placebo, with primary endpoint measuring change in lung function at 52 weeks. Topline data is expected in the second half of 2027.
GlobeNewswire Inc. · Jun 17, 2026
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma, a clinical-stage biopharmaceutical company, announced Q1 2026 financial results and pipeline updates following its May 2026 IPO that raised $345 million in gross proceeds. The company is on track to complete enrollment of its MIST Phase 2b trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis by mid-2026, with topline data expected in H2 2027. Long-term open-label extension data presented at EULAR showed favorable tolerability over four years. AP02 (inhaled nintedanib) enrollment is underway in the AURA Phase 2 trial with results anticipated by end of 2027. The company projects its cash position of $123.1 million plus $316.1 million in IPO proceeds will fund operations into 2029.
GlobeNewswire Inc. · Jun 3, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AV
AVLN
Avalyn Pharma Inc. Common Stock
Buy
Sell
Market
Limit
Soon
AVLN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AVLN yet.
Related Tickers
Earnings